Bristol-Myers Squibb BMY
-
BMO Capital initiates coverage on a few of the big drug companies today: Eli Lilly ([[LLY]] -0.1%) and Merck ([[MRK]] -0.4%) are initiated with a Market Perform, and Bristol - Myers ([[ BMY ]] +0.1%) is ...
BMO Capital initiates coverage on a few of the big drug companies today: Eli Lilly ( LLY -0.1% ) and Merck ( MRK -0.4% ) are initiated with a Market Perform, and Bristol - Myers ( BMY +0.1% ) is started with an Outperform . Post your comment!
-
Amylin (AMLN) has apparently attracted interest from potential suitors including Pfizer (PFE), AstraZeneca (AZN), Bristol - Myers ( BMY ) and Sanofi (SNY), all of which have signed confidentiality ...
… AMLN ) has apparently attracted interest from potential suitors including Pfizer ( PFE ), AstraZeneca ( AZN ), Bristol - Myers ( BMY ) and Sanofi ( SNY ), all of which have signed confidentiality agreements on the drugmaker's sale process …
-
New Morningstar Analyst Report - Gilead Sciences
… which contains Truvada and Bristol - Myers ' Sustiva, is the first pill ..... Martin, who was previously Bristol - Myers ' director of antiviral chemistry ..... which combines Truvada with Bristol - Myers Squibb 's BMY Sustiva, offers convenience …
-
Teva Pharmaceuticals' Disappointing Results
… the CEO position as of May 9th and was replaced by Jeremy Levin, a respected industry veteran coming out of Bristol - Myers Squibb ( BMY ). One reason for the gloomy reaction to Teva's first quarter Complete Story »
-
New Morningstar Analyst Report for Biogen Idec Inc
… and Steve Holzman as head of corporate development (previously at Millennium and Infinity). Bruce Ross, a Bristol - Myers Squibb veteran, retired from the board in June 2010; longtime director William Young has taken over his role as independent …
-
New Morningstar Analyst Report - Amgen
… and cheaper generic bisphosphonates; Vectibix competes with Roche's RHHBY Avastin and Eli Lilly LLY and Bristol - Myers Squibb 's BMY Erbitux. If Amgen's late-stage pipeline disappoints, the company could be forced to seek a large acquisition …
-
New Morningstar Analyst Report for Rigel Pharmaceuticals, Inc.
… the market for an oral RA treatment. A number of firms have oral RA drugs in the pipeline, including Pfizer, Bristol - Myers Squibb BMY , Vertex VRTX, and a joint venture between Eli Lilly LLY and Incyte INCY. Within this group, Pfizer's tofacitinib …
-
Lexicon's Diabetes Drug Candidate Approaching Prime Time for Partnering; Stock Remains Undervalued
… We also see the positive opinion from European regulators on Bristol 's BMY SGLT2 inhibitor dapagliflozin as an encouraging development ..... which may be able to avoid some of the side effects seen with Bristol 's compound.
-
New Morningstar Analyst Report - Exelixis, Inc.
… from the compound, Glaxo and Bristol 's decision to pass up the drug ..... originally partnering cabozantinib with Bristol - Myers Squibb BMY , Exelixis regained full rights ..... cabozantinib's program. While Bristol 's decision to pass on the compound …
-
Bristol-Myers Squibb Company - Shareholder/Analyst Call
Bristol - Myers Squibb Company ( BMY ) May 01, 2012 10:00 am ET Executives James M. Cornelius - Non-Executive Chairman Sandra Leung - Senior Vice President …